Blood Cancer Trials Decoded: Navigating Multiple Myeloma and Acute Myeloid Leukemia episode artwork

EPISODE · Dec 5, 2024 · 24 MIN

Blood Cancer Trials Decoded: Navigating Multiple Myeloma and Acute Myeloid Leukemia

from Moving Medicine Forward · host CTI Clinical Trials

In this episode of #MovingMedicineForward – The Podcast, CTI experts Chad Jones & Eric Clayton discuss challenges in clinical research surrounding Acute Myeloid Leukemia (AML) & Multiple Myeloma (MM). They explore the complexities of designing & conducting clinical trials, the importance of site selection, & how CTI’s expertise enhances trial outcomes. Additionally, they touch on key advancements to watch at the 66th American Society of Hematology Annual Meeting. During the episode, Eric explains how, “These are some of the first times that these therapies are being tried in human participants, & that innovative experimentation is what makes this work so exciting.” 0:22 Challenges in clinical research for Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM), with insights from CTI experts Chad Jones, Sr. Director of Project Management and Oncology Strategy Lead, and Eric Clayton, Clinical Project Manager III.  0:51 Overview of AML and MM, and why these diseases are particularly difficult to treat.  1:32 Key challenges in designing and conducting clinical trials for AML and MM.  3:19 How site selection and management impact trial success, and challenges Contract Research Organizations (CROs) face when recruiting qualified sites.  5:14 How CTI's expertise supports sponsors and improves trial outcomes.  6:38 The importance of maintaining proper chain of custody.  9:53 Key treatments and advancements in hematology to watch at the 66th ASH Annual Meeting.  10:33 Visit CTI at booth #454 at ASH.  10:41 Regulatory considerations for treatments and how CTI navigates this process for patients.  12:31 Collaboration between CROs, pharmaceutical companies, and academic institutions to accelerate research.  13:12 Unmet needs in AML and MM research and how the industry can address them.  14:16 Challenges in improving patient outcomes for MM and AML.  16:22 How CTI mitigates patient retention during clinical trials.  18:33 Strategies for recruiting critically ill MM and AML patients.  21:41 CTI is recruiting a Sr. Medical Director in Hematology/Oncology. Apply now: Senior Medical Director - Hematology/Oncology - Level Dependent Upon Experience | Join The CTI Team  

In this episode of #MovingMedicineForward – The Podcast, CTI experts Chad Jones & Eric Clayton discuss challenges in clinical research surrounding Acute Myeloid Leukemia (AML) & Multiple Myeloma (MM). They explore the complexities of designing & conducting clinical trials, the importance of site selection, & how CTI’s expertise enhances trial outcomes. Additionally, they touch on key advancements to watch at the 66th American Society of Hematology Annual Meeting. During the episode, Eric explains how, “These are some of the first times that these therapies are being tried in human participants, & that innovative experimentation is what makes this work so exciting.” 0:22 Challenges in clinical research for Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM), with insights from CTI experts Chad Jones, Sr. Director of Project Management and Oncology Strategy Lead, and Eric Clayton, Clinical Project Manager III.  0:51 Overview of AML and MM, and why these diseases are particularly difficult to treat.  1:32 Key challenges in designing and conducting clinical trials for AML and MM.  3:19 How site selection and management impact trial success, and challenges Contract Research Organizations (CROs) face when recruiting qualified sites.  5:14 How CTI's expertise supports sponsors and improves trial outcomes.  6:38 The importance of maintaining proper chain of custody.  9:53 Key treatments and advancements in hematology to watch at the 66th ASH Annual Meeting.  10:33 Visit CTI at booth #454 at ASH.  10:41 Regulatory considerations for treatments and how CTI navigates this process for patients.  12:31 Collaboration between CROs, pharmaceutical companies, and academic institutions to accelerate research.  13:12 Unmet needs in AML and MM research and how the industry can address them.  14:16 Challenges in improving patient outcomes for MM and AML.  16:22 How CTI mitigates patient retention during clinical trials.  18:33 Strategies for recruiting critically ill MM and AML patients.  21:41 CTI is recruiting a Sr. Medical Director in Hematology/Oncology. Apply now: Senior Medical Director - Hematology/Oncology - Level Dependent Upon Experience | Join The CTI Team

NOW PLAYING

Blood Cancer Trials Decoded: Navigating Multiple Myeloma and Acute Myeloid Leukemia

0:00 24:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

The Health Odyssey: Navigating Tomorrow's Medicine Podcast Welcome to 'The Health Odyssey: Navigating Tomorrow's Medicine,' where we embark on an adventurous journey through the ever-evolving world of healthcare. Each episode is like a treasure map, guiding you through the rich tapestry of ancient healing arts mixed with futuristic tech wizardry. We’ll chat about the wild west of health data privacy, the corporate giants reshaping our care, and the mind-bending potential of psychedelics for mental wellness. Think of us as your trusty sidekicks, unraveling the mysteries of modern medicine while keeping it real and relatable. Let’s dive into the stories, the science, and the soul of healthcare, paving the way for a healthier tomorrow. Lynne's Podcast Lynne August MD Dr. A offers her interpretations and applications of Dr. Revici’s profound research at DrRevici.com and the Revici Journal. Dr. Revici was arguably fifty to one hundred years ahead of his time in his application of quantum physics to medical sciences. As a once-aspiring physicist, this alone propelled Dr. A to Dr. Revici. As a physician, she felt compelled, and in some palpable way responsible, to understand Dr. Revici’s ability to control pain and achieve remissions in terminal cancer patients with his non-toxic “guided chemotherapy”, even many cancers that conventional therapy failed to control. Most of the time his questions and solutions were as unprecedented as they were effective. While Dr. Revici was primarily focused on cancer, Dr. A’s research and therapeutics to prevent and treat all chronic and degenerative disease can transform 21st century medicine. Pain and Sleep Center podcast Dr. Ryan P. Robinson Join Dr. Ryan P. Robinson and his team weekly as they charge forward in their teams mission of a healthier, well rested and energized nation! The Ten Commandments Chad Boersema Many focus on MAKING disciples, we hope to help in the process of BEING a disciple of Jesus. Understanding the ten commandments can be a good place to reflect on, as they were one of Israel's first introductions to learning how to relate to God and live in His way. Jesus also references the commandments in his sermon on the mount saying, “...whoever does them [the commandments] will be called great in the kingdom of heaven.” (Matthew 5:19) Looking forward to exploring these with you! Thanks for listening!web - jesusdisciple.info facebook - facebook.com/jesusdisciple.info twitter - twitter.com/fellow_disciple instagram - instagram.com/jesusdisciple.info

Frequently Asked Questions

How long is this episode of Moving Medicine Forward?

This episode is 24 minutes long.

When was this Moving Medicine Forward episode published?

This episode was published on December 5, 2024.

What is this episode about?

In this episode of #MovingMedicineForward – The Podcast, CTI experts Chad Jones & Eric Clayton discuss challenges in clinical research surrounding Acute Myeloid Leukemia (AML) & Multiple Myeloma (MM). They explore the complexities of designing &...

Can I download this Moving Medicine Forward episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!